Status:
COMPLETED
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
Lead Sponsor:
Stanford University
Conditions:
Acute Disease
Myelodysplastic Syndromes
Eligibility:
All Genders
51-60 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disord...
Detailed Description
To learn whether a new preparative regimen to prepare patients for bone marrow transplantation is useful in patients above 50 years of age and whether it is useful in patients with myelodysplastic syn...
Eligibility Criteria
Inclusion
- 1) Patients aged 51-60 with acute non-lymphocytic leukemia in first or subsequent remission and acute lymphocytic leukemia in first remission with high risk features which include elevated white blood cell count at presentation, cytogenetic abnormalities, extramedullary leukemia, ALL in greater than first remission and patients with chronic myelogenous leukemia at any stage who have a histocompatible sibling donor.
- 2\) Patients with myelodysplastic syndrome including patients with refractory anemia with excess blasts or refractory anemia with excess blasts in transformation.
- 3\) Patients with myeloproliferative disorders which give them poor long-term disease-free survival, such as myeloid metaplasia or myeloid fibrosis.
- 4\) Patients with secondary myelodysplasia following cytotoxic chemotherapy.
Exclusion
- Organ dysfunction
Key Trial Info
Start Date :
September 1 1992
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00186342
Start Date
September 1 1992
End Date
January 1 2009
Last Update
December 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305